Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss.  GLP-1 medications were originally intended to treat type 2 diabetes, but a growing number of people are using it for weight loss.

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.

Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know about these game-changing medications.

The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose medical interventions for weight management. Some critics argue that using the drugs is akin to "taking a shortcut," overlooking the complex factors that contribute to obesity.

New year, new you! Getting healthy is a popular resolution and to meet goals, some people may turn to weight-loss drugs for help. As certain weight-loss drugs have become increasingly popular, scammers are taking notice and coming out of the woodwork to cash in on trends.

According to that study, those who use GLP-1 dugs, such as Wegovy and Ozempic, cut their grocery spend by about 6% during the first few months after starting their prescription, translating to $416 annually. The impact is even greater in higher-income households earning over $125,000, who reduce their grocery spending by 9%, or $690, annually.

Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.